checkAd

    DGAP-News  293  0 Kommentare Biotest AG: Annual general meeting approves payout of dividend

    DGAP-News: Biotest AG / Key word(s): AGM/EGM
    Biotest AG: Annual general meeting approves payout of dividend

    12.05.2016 / 17:29
    The issuer is solely responsible for the content of this announcement.

    ---------------------------------------------------------------------------


    PRESS RELEASE

    Biotest AG: Annual general meeting approves payout of dividend

    - Dividend payout of EUR 0.02 per ordinary share and EUR 0.04 per
    preference share

    Dreieich/ Frankfurt a. M., 12 May 2016. At the annual general meeting (AGM)
    held on 12 May 2016 in Frankfurt/ Main, shareholders of Biotest AG approved
    the payment of a dividend. With 74,4 percent of the ordinary share capital
    represented at the meeting, a payment of EUR 0.02 per ordinary share and
    EUR 0.04 per preference share was resolved with a high degree of approval.
    The overall dividend payment will amount to EUR 1.2 million.

    The annual general meeting, with 257 shareholders present, formally
    discharged the members of the Management Board and Supervisory Board for
    financial year 2015.

    The full text of the speech given by the CEO of Biotest AG, Dr. Bernhard
    Ehmer, at the AGM is available at: http://www.biotest.com/de/en/
    investor_relations/shareholders_meeting.cfm

    About Biotest
    Biotest is a provider of plasma proteins and biological drugs. With a value
    added chain that extends from pre-clinical and clinical development to
    worldwide sales, Biotest has specialised primarily in the areas of clinical
    immunology, haematology and intensive medicine. Biotest develops and
    markets immunoglobulins, coagulation factors and albumins based on human
    blood plasma. These are used for diseases of the immune and haematopoietic
    systems. In addition Biotest develops monoclonal antibodies in the
    indications of cancer of plasma cells and systemic lupus erythematosus
    which are produced by recombinant technologies. Biotest has more than 2,300
    employees worldwide. The preference shares of Biotest AG are listed in the
    SDAX on the Frankfurt stock exchange.

    IR contact
    Dr. Monika Buttkereit
    phone: +49-6103-801-4406
    email: investor_relations@biotest.de

    PR contact
    Dirk Neumüller
    phone: +49-6103-801-269
    email: pr@biotest.de

    Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de

    Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
    Preference shares: securities' ID No. 522723; ISIN DE0005227235
    Listing: Prime Standard
    Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
    Munich, Stuttgart

    Disclaimer

    This document contains forward-looking statements on overall economic
    development as well as on the business, earnings, financial and assets
    position of Biotest AG and its subsidiaries. These statements are based on
    current plans, estimates, forecasts and expectations of the company and are
    thus subject to risks and elements of uncertainty that could result in
    significant deviation of actual developments from expected developments.
    The forward-looking statements are only valid at the time of publication.
    Biotest does not intend to update the forward-looking statements and
    assumes no obligation to do so.


    ---------------------------------------------------------------------------

    12.05.2016 Dissemination of a Corporate News, transmitted by DGAP - a
    service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    The DGAP Distribution Services include Regulatory Announcements,
    Financial/Corporate News and Press Releases.
    Media archive at www.dgap-medientreff.de and www.dgap.de

    ---------------------------------------------------------------------------

    Language: English
    Company: Biotest AG
    Landsteinerstraße 5
    63303 Dreieich
    Germany
    Phone: 0 61 03 - 8 01-0
    Fax: 0 61 03 - 8 01-150
    E-mail: investor_relations@biotest.de
    Internet: http://www.biotest.de
    ISIN: DE0005227235, DE0005227201
    WKN: 522723, 522720
    Indices: SDAX
    Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
    Unofficial Market in Berlin, Dusseldorf, Hamburg,
    Stuttgart


    End of News DGAP News Service
    ---------------------------------------------------------------------------

    463345 12.05.2016


    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-News Biotest AG: Annual general meeting approves payout of dividend DGAP-News: Biotest AG / Key word(s): AGM/EGM Biotest AG: Annual general meeting approves payout of dividend 12.05.2016 / 17:29 The issuer is solely responsible for the content of this announcement. …

    Schreibe Deinen Kommentar

    Disclaimer